Market Pulse Archives

Dec. 3, 2021, 6:48 a.m. EST

Roche unit develops new testing kits to detect mutations in omicron variant

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Roche Holding AG (ROG)

or Cancel Already have a watchlist? Log In

By Barbara Kollmeyer

CH:ROG

Roche /zigman2/quotes/206324342/delayed CH:ROG +0.13% and its newly acquired subsidary TIB Molbiol said Friday that they have developed three new research test kits to differentiate mutations in the omicron variant of coronavirus that causes COVID. The Swiss pharmaceutical announced the new kits are among the first to specify those mutations, and can help manage the pandemic. "Use of these new tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines, and public health interventions," said the company in a statement . Roche said after analyzing publicly available sequences of the omicron variant, it has concluded that all Roche PCR tests correctly identify the new variant.

/zigman2/quotes/206324342/delayed
CH : Switzerland: SWX
CHF 349.55
+0.45 +0.13%
Volume: 516,780
Jan. 27, 2022 3:14p
P/E Ratio
21.51
Dividend Yield
2.60%
Market Cap
CHF299.94 billion
Rev. per Employee
CHF588,922
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.